StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3099% above fair value
$166.43−0.10 (-0.06%)

Close on Nov 20, 2026Market cap $206.43BP/E –Yield 1.90%

Gilead Sciences Wholesaler revenue concentration by Year

Wholesaler revenue concentration — Cardinal Health, Inc. (% of total revenues) (%)

Gilead Sciences Wholesaler revenue concentration: 2,900.0% in FY2025, unchanged from a year earlier.

Latest, FY2025
2,900.0%
Period ended Dec 31, 2025
Change on a year earlier
0.0 pts
2,900.0% in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-24) ↗

Reported in Form 10-K Note 2 Summary of Significant Accounting Policies.

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedWholesaler revenue concentration — Cardinal Health, Inc. (% of total revenues) (%)Year on yearSource
FY2025Dec 31, 20252,900.0%0.0 ptsForm 10-K (filed 2026-02-24) ↗
FY2024Dec 31, 20242,900.0%+100.0 ptsForm 10-K (filed 2026-02-24) ↗
FY2023Dec 31, 20232,800.0%+300.0 ptsForm 10-K (filed 2026-02-24) ↗
FY2022Dec 31, 20222,500.0%+300.0 ptsForm 10-K (filed 2025-02-28) ↗
FY2021Dec 31, 20212,200.0%+100.0 ptsForm 10-K (filed 2024-02-23) ↗
FY2020Dec 31, 20202,100.0%0.0 ptsForm 10-K (filed 2023-02-22) ↗
FY2019Dec 31, 20192,100.0%–Form 10-K (filed 2022-02-23) ↗

Cite this data

StockData. (2026). Gilead Sciences Wholesaler revenue concentration (%), annual FY2019–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/conc-cardinal-rev

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.

See a number that looks wrong?